“No Compounding Allowed” Drugs Would Be Established Under Senate Draft Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
A $15,000 annual establishment fee for “compounding manufacturers” could net FDA $45 million for inspecting those compounding sites.